The National Institutes of Health is undertaking an extended study of the health effects that East Palestine, Ohio, residents ...

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Asian shares are mixed and oil prices have advanced after the escalation of conflict in the Middle East hit Wall Street.

Deputy DA Andrew Wood ruled Eric Salisbury's fatal shooting of Manuel Garza was justified self-defense, releasing bodycam ...

This discount is shown at checkout, if applicable. Eli Lilly and Company says it will acquire the gene therapy start-up Verve Therapeutics for $1.3 billion. Verve’s lead drug candidate, VERVE-102, ...